Navigation Links
Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
Date:3/19/2008

New Hope Available for the Millions Suffering from these Diseases

LOS ANGELES, March 19 /PRNewswire-USNewswire/ -- Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are two serious and debilitating diseases with no confirmed cause and limited treatment options. However, results of a new comprehensive literature study propose a simplified treatment process that could help alleviate symptoms for patients suffering from these diseases.

Kent Holtorf, M.D., medical director of the Holtorf Medical Group Center for Endocrine, Neurological and Infection Related Illness in Torrance, Calif., is advising a simplified treatment process that may help alleviate CFS and FM symptoms. From an extensive review of more than 50 published studies that assessed adrenal function in CFS and FM patients, Dr. Holtorf found that the majority of CFS and FM patients displayed abnormal adrenal function due to hypothalamic-pituitary dysfunction. The comprehensive review also showed that the majority of patients could be treated for this adrenal dysfunction. Dr. Holtorf's analysis, recently published in the Journal of Chronic Fatigue Syndrome, demonstrated that patients that were given cortisol as part of a multi-system treatment experienced significant improvement in their symptoms.

"My review of existing studies suggests that a treatment protocol of early administration of cortisol may help improve and reduce the symptoms of chronic fatigue syndrome and fibromyalgia," said Dr. Holtorf. "This research provides a new understanding that treating the known causes of illness in CFS and FM can improve the symptoms and quality-of-life of patients who suffer from these conditions."

CFS and FM primarily affect women in their 30s and 40s. According to the Centers for Disease Control and Prevention (CDC) more than one million Americans suffer from CFS while it is estimated that FM affects about 2 percent of the U.S. population. Unfortunately, both of these diseases are poorly understood by many physicians and there is no generally accepted test to accurately detect them. In addition, many CFS and FM patients express frustration because there is no clear treatment path for their conditions.

Dr. Holtorf's research was further confirmed in an observational study following the conditions of 500 patients from his clinic, where all of the patients were given cortisol as part of their treatment protocol:

-- 94 percent showed improvement by the fourth visit;

-- 75 percent noted significant improvement;

-- 62 percent reported substantial improvement; and

-- Energy levels and a general sense of well-being for patients doubled by the fourth visit.

The effectiveness of this multi-system treatment was further confirmed through the analysis of the cumulative findings of over 40 independent physicians and over 5,000 patients.

As shown in the Journal of Chronic Fatigue Syndrome study, cortisol doses of 5-to-15 mg a day have been shown to be safe, with little or no associated risk while having the potential for significant benefit for CFS and FM patients.

"Cortisol treatment carries significantly less risk and a greater potential for benefit than treatments considered to be the standard of care for both conditions," Dr. Holtorf explains.

What is Chronic Fatigue Syndrome?

Chronic fatigue syndrome, or CFS, is a debilitating and complex disease characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity. Persons with CFS most often function at a substantially lower level of activity than they were capable of before the onset of illness. In addition, patients report various symptoms, such as weakness, muscle pain, impaired memory and/or mental concentration, insomnia, and post-exertional fatigue lasting more than 24 hours. In some cases, CFS can persist for years. The cause or causes of CFS have not been identified and no specific diagnostic tests are available.

What is Fibromyalgia?

Fibromyalgia or FM is a chronic pain condition characterized by generalized muscular pain and fatigue. Fibromyalgia typically involves pain in the muscles, ligaments and tendons and related sleep and quality of life disturbances. This condition is often referred to as a "syndrome" because it is a set of signs and symptoms that occur together. The disease is often misunderstood because its symptoms are quite common; however, medical studies have proven that fibromyalgia does indeed exist.

Kent Holtorf, M.D.

Kent Holtorf, M.D. is an expert in the treatment of chronic fatigue syndrome, fibromyalgia, complex endocrine dysfunction and chronic infections (including EBV, HHV6 and Lyme disease). Dr. Holtorf received his doctorate of medicine from St. Louis University with residency training at UCLA. He has personally trained numerous physicians across the country to effectively treat chronic fatigue syndrome, fibromyalgia and chronic infectious diseases. Additionally, Dr. Holtorf was the founding medical director and developed the protocols for Fibromyalgia and Fatigue Centers and other centers across the country.

CONTACT: Julian Teixeira of Zeno Group, +1-202-965-7808


'/>"/>
SOURCE Zeno Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
2. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
8. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
9. NPS Reports Successful GATTEX(TM) Extension Study
10. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
11. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017  Hoy, ... lanzaron Access Accelerated, una iniciativa global para avanzar el ... y atención en países de renta baja y baja-media ... alcanzado un punto de crisis, particularmente en países de ... 80 por ciento de las muertes relacionadas con NCD. ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
(Date:1/19/2017)... ... 2017 , ... The CHP suggests that California drivers can avoid hydroplaning as ... and increasing the space between themselves and other vehicles, according to a January 3 ... R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
Breaking Medicine News(10 mins):